This agreement is expected to provide the physicians greater choice and flexibility in offering patients the newest isotope available.
According to IsoRay, the Cesium-131 seed offers a significantly shorter half-life than the two other isotopes commonly used for brachytherapy, which results in a substantially faster delivery of therapeutic radiation, lower probability of cancer cell survival and reduction of the longevity of common brachytherapy side effects.
Dwight Babcock, chairman and CEO of IsoRay, said: We are very pleased to announce this collaboration with BrachySciences. Management believes this distribution agreement will enable us to increase the sales of Cesium-131 within the prostate cancer therapy market.
This supports our ongoing strategy of driving sales by adding an additional outside distribution channel to augment our current sales staff. We look forward to a close working relationship with BrachySciences that will help us further penetrate the brachytherapy market.
IsoRay is a medical isotope and medical device company. IsoRay Medical, subsidiary of IsoRay, Inc. began production and sales of its initial FDA-cleared product, the IsoRay 131Cs brachytherapy seed, in October 2004 for the treatment of prostate cancer.